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Abstract
Background: Astrocytomas are the most common type of primary central nervous system
tumors. They are frequently associated with genetic mutations that deregulate cell cycle and render
these tumors resistant to apoptosis. STAT3, signal transducer and activator of transcription 3,
participates in several human cancers by inducing cell proliferation and inhibiting apoptosis and is
frequently activated in astrocytomas.
Methods: RNA interference was used to knockdown STAT3 expression in human astrocytes and
astrocytoma cell lines. The effect of STAT3 knockdown on apoptosis, cell proliferation, and gene
expression was then assessed by standard methods.
Results: We have found that STAT3 is constitutively activated in several human astrocytoma cell
lines. Knockdown of STAT3 expression by siRNA induces morphologic and biochemical changes
consistent with apoptosis in several astrocytoma cell lines, but not in primary human astrocytes.
Moreover, STAT3 is required for the expression of the antiapoptotic genes survivin and Bcl-xL in
the A172 glioblastoma cell line.
Conclusion: These results show that STAT3 is required for the survival of some astrocytomas.
These studies suggest STAT3 siRNA could be a useful therapeutic agent for the treatment of
astrocytomas.
Background
Astrocytomas are the most common type of primary
tumors of the central nervous system. These tumors arise
from either astrocytes or their progenitor cells [1] and rep-
resent the second leading cause of cancer related deaths in
children and in young adults [1–5]. It is also the second
fastest growing cause of cancer deaths among those over
65, and unlike lung cancer (first) and melanoma (third),
no behavioral changes have been shown to reduce risk [6].
Astrocytomas are divided into four grades based on the
malignancy of the tumor. Glioblastoma multiforme
(GBM), grade IV, is the most common type with the worst
prognosis [1–5]. Average post-operative survival after
tumor resection is less than two years [1–5]. In young
adults, grade IV astrocytomas usually progress from lower
grade astrocytomas, while in older patients it frequently
arises  de novo [1–4]. Progressive astrocytomas are fre-
quently associated with loss of function mutations in p53,
Rb and Ink4a/p16 genes as well as amplifications of
PDGFR, MDM2 and Cdk4 genes [5,7–13]. These
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mutations cause a deregulation of cell cycle and render
these tumors resistant to apoptosis.
STATs, signal transducers and activator of transcription,
are a family of transcription factors that transmit signals
from cell surface receptors directly to the nucleus [14].
Activation of all the STAT proteins is caused by phospho-
rylation of a single tyrosine residue that leads to dimeriza-
tion via an intermolecular SH2 phosphotyrosine
interaction [15–18]. The dimerized STATs then translo-
cate to the nucleus where they regulate gene expression by
binding directly to high affinity DNA binding sites or by
associating with other transcription factors [19–24]. They
play a critical role in mediating cytokine and growth factor
signaling involved in cell growth, differentiation and sur-
vival [25–28]. Among the seven members of mammalian
STAT family, STAT3 has been most strongly implicated in
oncogenesis [29]. STAT3 is ubiquitously expressed in
mammalian cells and is activated by cytokines such as IL-
6 family members as well as growth factors such as EGF
and PDGF [30]. Transient STAT3 activation is required for
astrocytic differentiation [31]. However, the role of STAT3
signaling in adult astrocytes is unclear.
Although spontaneous mutations in the STAT3 gene have
not been associated with tumorigenesis, constitutively
activated STAT3 is found in a wide variety of human
tumors including multiple myelomas, breast, ovarian,
prostate, and head and neck tumors [31–37]. There is sub-
stantial evidence to implicate STAT3 activation in tumor
progression. A number of studies have demonstrated that
the transformation process induced by diverse oncogenic
protein tyrosine kinases is dependent on STAT3 activation
[37–39]. Inhibition of STAT3 signaling in a number of
tumor cell lines with either small molecular inhibitors to
block protein tyrosine kinases (PTKs) or with dominant
negative/antisense STAT3 causes a decrease in cell viability
and subsequent apoptosis [31,34,40]. Elevated STAT3
activity has been shown to render cells resistant to apop-
tosis by inducing anti-apoptotic genes such as Bcl2, Bcl-
xL, and Mcl-1[37]. Recently it has been shown that STAT3
is constitutively activated in astrocytomas [41]. Here we
show that knockdown of STAT3 expression by siRNA
reduces levels of survivin and Bcl-xL expression and trig-
gers apoptosis in astrocytoma cells.
Methods
Cell Lines and Culture Conditions
The human astrocytoma cell lines A172 and T98G were
obtained from the American Type Culture Collection
(Rockville, MD). The U251-MG cell line was graciously
donated by Dr. George Perides (Tufts-NEMC). These cell
lines were derived from grade IV astrocytomas – glioblas-
toma multiforme (GBM). Normal human astrocytes
(NHA) were obtained from ScienCell (San Diego, CA).
A172 and U251-MG cells were cultured in DMEM (ATCC,
Rockville, MD) supplemented with 10% FCS. T98G was
cultured in MEM (ATCC, Rockville, MD) supplemented
with 10% FCS. Normal human astrocytes (NHA) were
cultured in astrocyte medium (ScienCell, San Diego, MD).
STAT3 siRNA and siRNA transfections
We designed a double stranded siRNA oligonucleotide
against STAT3 (5'-AAC AUC UGC CUA GAU CGG CUA
dTdT-3'; 3'-dTdT GUA GAC GGA UCU AGC CGA U-5')
and had it synthesized by Dharmacon Research, Inc
(Lafayette, CO). Oligofectamine (Invitrogen, Carlsbad,
CA) was used as the transfection reagent following manu-
facturer's directions using 200–600 nmol of siRNA per 10
cm dish. Cells were incubated for 24 hrs in Opti-MEM, at
which point appropriate media for the cells supplemented
with 30% FCS was added. The cells were then incubated
for the amount of time indicated in the Figure Legends.
Immunoblotting
For Western blot analysis, cells were harvested and lysed
with RIPA buffer (0.15 M NaCl, 1% NP40, 0.01 M desox-
ycholate, 0.1% SDS, 0.05 M Tris-HCl pH 8.0, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl flu-
oride, and 10 µg/ml each of aprotinin, pepstatin, and leu-
peptin). For STAT3 analysis, protein samples were
electrophoresed on a 10% SDS-PAGE gels for 90 min. at
150 mV and transferred onto Immobilon membranes
(Millipore, Bedford, MA) for 60 min at 100 mV in 10%
methanol transfer buffer. For caspase-3 analysis the pro-
tein samples were separated on a 15% SDS-PAGE and
transferred onto Immobilon membranes (Millipore, Bed-
ford, MA) at 20 mV for 20 min and 80 mV for 2 hrs in 20%
methanol transfer buffer. The membranes were then
probed with each antibody as indicated. Immunoreactive
proteins were visualized using an enhanced chemilumi-
nescence detection system (Amersham Pharmacia Bio-
tech). Anti-phospho-STAT3, anti-STAT3, anti-cleaved
Caspase 3, anti-Bcl-xL and anti 42–44 MAP kinase were
obtained from Cell Signaling (Beverly, MA). Anti-β-actin
antibody was obtained from Sigma (St. Luis, MO).
Cell number assay
For cell proliferation assays, cells were incubated for 72
hrs in 96-well plates in quadruplicates. Viable cell number
was determined by using MTS assay according to the man-
ufacturer's instructions (CellTiter 96 AQ Non-radioactive
proliferation kit, Son Luis, CA). The absorbance was
measured at 490 nm with a 96-well plate reader.
FACS analysis
Cells were treated with siRNA as described above. After 96
hours, cells were isolated and stained with annexin V-
EGFP (BD Biosciences Clontech, Palo Alto, CA). Cells
were analyzed using FACS for fluorescence of annexin VBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/23
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positive cells. The fraction of annexin V positive cells in
the siRNA treated population was determined using the
super-enhanced DMax method of WinList software (Ver-
ity Software House, Topsham, ME).
Northern blot analysis
The A172 cell line was treated with STAT3 siRNA as
described previously and RNA purified with TRIzol (Invit-
rogen, Carlsbad, CA). 10 µg of each RNA sample was
loaded per well. After transferring onto a nylon mem-
brane (Ambion, Austin, TX), it was probed with a survivin
probe (Resgen) or p21 (gift of Sam Lee) labeled with 32P.
Hybridizations were performed with Express Hyb (BD
Biosciences Clontech, Palo Alto, CA) and washed follow-
ing the manufacturers protocol. Blots were exposed to
Kodak MS film overnight and developed. Blots were then
quantitated using a Molecular Dynamics
phosphorimager.
Results
STAT3 is constitutively activated in astrocytoma cell lines
To determine whether STAT3 is expressed and constitu-
tively activated in astrocytoma cell lines, we compared the
level of STAT3 expression and tyrosine 705 STAT3 phos-
phorylation in normal human astrocytes (NHA) to that of
three astrocytoma cell lines. Western Blot analysis with
anti-STAT3 and anti-phosphotyrosine STAT3 antibodies
revealed that STAT3 was overexpressed and overactivated
in astrocytoma cells as compared to primary astrocytes
(Figure 1). Reprobing the blot with anti-β-actin shows
that variability in protein loading could not account for
the observed differences in STAT3 expression.
STAT3 RNAi specifically reduces STAT3 expression in 
astrocytoma cell lines
Recent studies show that constitutive activation of STAT3
in variety of tumors directly contributes to their oncogenic
potential by inducing proliferation and inhibiting apop-
tosis [40,41]. Thus, we sought to determine the effect of
inhibiting STAT3 expression in astrocytoma cells.
To inhibit STAT3 expression in astrocytoma cells, we used
the RNAi method adapted for mammalian cell culture by
Elbashir et al [42]. A number of 21 bp double stranded
RNAs to human STAT3 were synthesized and tested for
their ability to knockdown STAT3 expression in astrocyto-
mas. Transfection of cells with one of these STAT3 siRNAs
(Figure 2a) resulted in a highly significant and reproduci-
ble decrease in STAT3 expression levels as judged by West-
ern Blotting (Figure 2b). The degree of knockdown
achieved ranged from 75–95% depending upon the
experiment and cell line used. STAT3 siRNA inhibited
STAT3 expression in normal human astrocytes (NHA) as
well as in astrocytoma cell lines (Figure 2b). Mock trans-
fection with oligofectamine or with an siRNA to the green
fluorescent protein (GFP) failed to reduce STAT3 expres-
sion. The effect of STAT3 siRNA was specific in that it
failed to knock down expression of the unrelated proteins
β-actin or Map Kinase. STAT3 knockdown by siRNA was
found to be time dependent with the maximum effect
achieved at 48–72 hrs of siRNA treatment (Figure 2c).
This siRNA is human specific and does not efficiently
knockdown expression of murine STAT3 (Data not
shown).
STAT3 RNAi induces morphology changes and decreases 
viability in astrocytoma cell lines
We noted that upon STAT3 siRNA treatment of some of
the astrocytoma lines that cultures were less confluent and
some cells became smaller and rounder than control oli-
gofectamine treated cells (Figure 3a). Consistent with this,
there were fewer cells in both A172 and U251-MG cul-
tures treated with STAT3 siRNA as compared to control
oligofectamine treated cultures 72 hours post transfection
(Figure 3b). Transfecting A172 cells a second time with
STAT3 siRNA 48 hours after the initial transfection
resulted in an even greater reduction in cell number
(>90% in A172 and 65% in U251) as compared to oligo-
fectamine controls (data not shown). Viability of normal
human astrocytes (NHA) was not significantly affected by
STAT3 siRNAi treatment. Another astrocytoma cell line,
T98G, was only slightly affected by reductions in STAT3
expression (Figure 3b). Thus, not all astrocytoma cell lines
STAT3 is expressed and active in GBM cell lines Figure 1
STAT3 is expressed and active in GBM cell lines. The 
indicated cell lines were lysed in RIPA buffer after serum 
starvation for 24 hrs. Cell lysates were subjected to electro-
phoresis on an SDS PAGE gel and processed for Western 
blotting with anti-phospho-Tyr-STAT3, anti-STAT3, or anti-
β-actin antibodies. NHA are primary human astrocytes. All 
other cell lines are grade IV astrocytoma (GBM).
NHA A172 T98 U251
α-pTyr STAT3
α-STAT3
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are equally responsive to STAT3 knockdown. The decrease
in cell number caused by STAT3 siRNA treatment of astro-
cytoma cells implies that STAT3 participates in cell cycle
progression, cell survival, or both. Staining A172 cells for
DNA content after STAT3 siRNA treatment showed an
increased proportion of cells in early S phase (data not
shown). This could be due to an S phase cell cycle block
or to preferential apoptosis of these cells in late S and G2/
M.
STAT3 RNAi induces apoptosis in astrocytoma cells
The cell number decreases observed in conjunction with
the morphological observations suggested that astrocy-
toma cells treated with STAT3 siRNA undergo apoptosis.
To confirm that these cells undergo apoptosis in response
to STAT3 knockdown, we examined three other indicators
of apoptosis in the A172 cell line. First, cultures of astro-
cytoma cells were stained Hoechst 33258 dye and scored
for apoptotic nuclei[43]. A significantly higher percentage
of apoptotic nuclei were observed in STAT3 siRNA treated
cells than in GFP siRNA or oligofectamine treated cells
(Figure 4a). Consistent with this observation, Western
blot analysis of astrocytoma cell extracts showed that
there is increased cleavage of caspase 3 in STAT3 siRNA
treated cells (Figure 4b). Finally, annexin V staining of
control and STAT3 siRNA treated cells followed by fluo-
rescence activated cell sorting analysis indicated a 77%
increase in the fraction of annexin V positive cells, further
confirming that these cells are undergoing apoptosis (Fig-
ure 4c)[44]. Together these data indicate that STAT3 regu-
lates an anti-apoptotic program in astrocytomas and that
inactivation of STAT3 leads to a rapid induction of
apoptosis.
Knockdown of STAT3 expression down regulates survival 
genes
Recent data indicate that constitutive activation of STAT3
induces the expression of a number of anti-apoptotic
genes including Bcl-xL, a member of the Bcl-2-family of
anti-apoptotic genes [32,45], and survivin, a member of
the IAP, inhibitors of apoptotic proteins family [46].
Moreover, both of these genes are expressed in astrocyto-
mas [47,48]. In order to determine whether these two
genes might be involved in the STAT3 mediated apoptotic
block in astrocytoma, Northern and Western blot analyses
were performed to examine the expression levels of these
two genes. Northern blot analysis showed that STAT3
siRNA reduced expression of survivin by 75% (Figure 5a).
Western blot analysis showed that Bcl-xL protein levels
were drastically reduced upon treatment with STAT3
siRNA. Thus, these data show that STAT3 regulates the
expression of at least two distinct antiapoptotic genes in
the A172 cell line.
Discussion
STAT3 is activated by a number of cytokines and growth
factors and has diverse functions during embryogenesis
and early development [25–28]. Due to the transient
nature of cytokine and growth factor signaling and the
presence of proteins such as SOCS, suppressor of cytokine
signaling, and PIAS, protein inhibitor of activated STAT,
that inhibit of STAT3 signaling, STAT3 activation under
normal physiological conditions is transient, lasting any-
where from several minutes to several hours [49]. How-
ever, during tumorigenesis there is often constitutive
activation of PTKs due to activating mutations or aberrant
growth factor or cytokine signaling. Constitutive PTK sig-
naling results in constitutive activation of STAT3[38]. It is
therefore not surprising that recent studies show that there
is persistent activation of STAT3 in a number of human
cancers including multiple myelomas, breast, ovarian and
prostate carcinomas and head and neck tumors [32–37].
The initial evidence that STAT3 signaling is critical to tum-
origenesis came from the observation that activation of
STAT3 is necessary for v-src induced transformation of
NIH3T3 cells [38,39]. Subsequent studies have shown
that STAT3 activation is crucial to cellular transformation
induced by a number of viral oncogenes [37]. Inhibition
Knockdown of STAT3 by siRNA in primary human astro- cytes and astrocytoma cells Figure 2
Knockdown of STAT3 by siRNA in primary human 
astrocytes and astrocytoma cells. A. Sequences of the 
synthetic siRNA duplex designed against human STAT3. B. 
The astrocytoma cell lines A172 and U251 and normal 
human astrocytes (NHA) cultured in 10 cm plates were 
transfected with 600 nmol STAT3 siRNA and after 72 hours 
processed for Western blotting with anti-STAT3 antibodies. 
The blots were subsequently stripped and reprobed with 
anti-β-actin or anti-Map Kinase antibodies as controls. C. 
A172 cells were transfected with 600 nmol STAT3 siRNA 
for the times indicated and processed for Western blotting 
with anti-STAT3 antibodies.
V
e
h
i
c
l
e
S
t
a
t
3
 
s
i
R
N
A
A.  Synthetic siRNA against STAT3
C.
B.
5’-CAU CUG CCU AGA UCG GCU AdTdT-3’
3’-dTdT GUA GAC GGA UCU AGC CGA U- 5’
V
e
h
i
c
l
e
S
t
a
t
3
 
s
i
R
N
A
G
F
P
 
s
i
R
N
A
NHA
α-STAT3
α-MAPK
V
e
h
i
c
l
e
S
t
a
t
3
 
s
i
R
N
A
G
F
P
 
s
i
R
N
A
U251 A172
α-STAT3
α-β-actin
0h   6h    1d     3d 
α-STAT3BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/23
Page 5 of 9
(page number not for citation purposes)
of STAT3 signaling with either dominant negative or
antisense oligonucleotides against STAT3 suppresses the
transformation process in some tumors [34,50]. Overex-
pression of a constitutively active mutant of STAT3 trans-
forms 3T3 cells in culture [51]. Finally, recent studies have
shown that treatment of tumor cells with inhibitors of
STAT signaling results in decreased cell viability and
induces apoptosis [40,41]. Together these findings
demonstrate that STAT3 signaling plays a critical role in
both the transformation process and tumor progression
in some types of cancer.
Ourselves and others have found STAT3 is constitutively
activated in astrocytomas and astrocytoma cell lines
[41,52]. This is consistent with the fact that human astro-
cytomas are often characterized by an amplification of
either growth factor genes, such as PDGF, growth factor
receptor genes, such as the EGF receptor, or cytokines such
as IL-6 that can lead to constitutive activation of STAT3
[53,54]. Not surprisingly, there was constitutive STAT3
activation in all astrocytoma cell lines tested. In contrast,
NHA showed relatively little STAT3 expression and
activation.
In order to determine the role of STAT3 in astrocytomas
directly, we have used RNAi to specifically knock down
the expression of STAT3 in several human astrocytomas.
Treatment of astrocytoma cell lines with STAT3 siRNA
resulted in morphologic and biochemical changes
indicative of apoptosis. These results are consistent with
STAT3 siRNA causes a decrease in cell number in glioblastoma cell lines Figure 3
STAT3 siRNA causes a decrease in cell number in glioblastoma cell lines. A. A172 cells were transfected with a 
STAT3 siRNA (bottom panel) or a control siRNA (top panel). Cells were photographed 72 hours post transfection at 200× 
magnification. B. A172, U251, T98G, and NHA cells were transfected with STAT3 siRNA or mock transfected with oligo-
fectamine (vehicle). Viable cell numbers were determined by MTS assay 72 hours after transfection. (*) indicates a P value 
<0.001.
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results previously observed with dominant negative
STAT3 in U251 cells [41]. Although STAT3 siRNA
decreased the amount of STAT3 present in NHA, it did not
have a significant effect on their viability. This suggests
that STAT3 may be an ideal target for cancer therapy since
inhibition of STAT3 signaling induces tumor cell death,
but does not kill normal astrocytes.
One mechanism by which STAT3 participates in tumori-
genesis is by inhibiting apoptosis through the induction
of anti-apoptotic genes. Biochemical studies have shown
that astrocytoma cells express a number of death receptors
but are resistant to death receptor mediated apoptosis
[55,56]. Other studies have shown that survivin is overex-
pressed in some tumors and that overexpression of the
gene is sufficient to block apoptosis in tumor cells
[48,57,58]. We have found that both Bcl-xL, a member of
the BCL2 family of proteins, and survivin are expressed in
A172 cells (Figure 5a &5b). Treating A172 cells with
STAT3 siRNA significantly reduces expression levels of
both of these genes. STAT3 responsive elements are found
in the promoter region of both of these genes, suggesting
Induction of apoptosis in human astrocytomas by STAT3 RNAi Figure 4
Induction of apoptosis in human astrocytomas by STAT3 RNAi. A. A172 cells were transfected with STAT3, GFP siR-
NAs, or mock transfected with oligofectamine (vehicle). After 72 hrs, cells were fixed in 4% paraformaldehyde and stained with 
25 µg/ml Hoechst 33258 dye to visualize apoptotic nuclei. The percentage of apoptotic cells (small bright nucleus) was deter-
mined for each of the treatments by counting five visual fields and at least 100 cells. B. A172 cells were transfected with STAT3 
siRNA or mock transfected with oligofectamine. Western blotting was performed 72 hrs post transfection. Blots were probed 
with α-STAT3, α-cleaved caspase 3 and α-β-actin antibodies. C. A172 cells were transfected with STAT3 siRNA (bottom 
panel) or mock transfected with oligofectamine (top panel). After 96 hours, cells were isolated and immunostained with EGFP 
coupled anti-annexin V antibody. Cells were sorted by FACS and annexin V positive cells counted. The region shaded in black 
(77%) corresponds the increase in annexin V positive cells relative to the mock transfected cells.
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that they are directly regulated by STAT3 [32,46]. Our
findings that Bcl-xL is regulated by STAT3 in astrocytoma
cell lines is consistent with previous data [41]. We are the
first to report that STAT3 also regulates survivin expres-
sion in astrocytoma. Taken together with our data that
knockdown of STAT3 can induce apoptosis, these findings
suggest that induction of Bcl-xL and survivin genes by
constitutively activated STAT3 promotes survival of astro-
cytoma cells.
Not all the astrocytoma cell lines examined responded
equally to STAT3 knockdown. This suggests that some
astrocytomas are not dependent on STAT3 for survival.
Further work is needed to determine whether this STAT3
independence has evolved from STAT3 dependent cells or
more likely is a result of the specific types of oncogenic
mutations in these tumors.
Data presented in this paper are consistent with the grow-
ing body of evidence suggesting STAT3 may be an impor-
tant therapeutic target in tumors including astrocytoma.
We are the first to report that an siRNA can induce apop-
tosis of astrocytoma cells. siRNAs are short oligonucle-
otides of 21–23 nucleotides in length that can be used in
vitro to produce sequence specific gene silencing of mam-
malian cells [59]. It has been shown that siRNAs can be
used effectively in vivo  to suppress gene expression in
adult mice [60,61]. siRNAs can be directly introduced into
the CNS to reduce endogenous gene expression [62].
These results suggest that siRNA may become a useful
clinical tool in the future. Since STAT3 signaling is impor-
tant for the survival of a number of human tumors, STAT3
siRNA could become an effective therapeutic agent for
STAT3 dependent tumors.
Conclusions
Knockdown of STAT3 expression by RNAi results in a
reduction in expression of Bcl-xL and survivin in A172
cells and leads to induction of apoptosis in this and other
astrocytoma cell lines.
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